This statistic shows the cost to bring a biopharmaceutical asset to market among mid-to-large cap biopharma companies from 2013 to 2020. According to the data, the cost to bring an asset to market was highest in 2018, with some *** billion U.S. dollars.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Deloitte. (May 24, 2021). Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies from 2013 to 2020 (in billion U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 04, 2026, from /statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte. "Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies from 2013 to 2020 (in billion U.S. dollars)." Chart. May 24, 2021. ÌÇÐÄÆƽâ°æ. Accessed August 04, 2026. /statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte. (2021). Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies from 2013 to 2020 (in billion U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 04, 2026. /statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte. "Average Cost to Bring a Pharmaceutical Asset to Market among mid Cap Biopharma Companies from 2013 to 2020 (in Billion U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 24 May 2021, /statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
Deloitte, Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies from 2013 to 2020 (in billion U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/ (last visited August 04, 2026)
Average cost to bring a pharmaceutical asset to market among mid cap biopharma companies from 2013 to 2020 (in billion U.S. dollars) [Graph], Deloitte, May 24, 2021. [Online]. Available: /statistics/825721/cost-to-bring-biopharmaceutical-assets-to-market-for-mid-cap-companies/
